MedTrace Logo

Effects of Pioglitazone in Calcific Aortic Valve Disease

NCT05875675 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-05-25

No results posted yet for this study

Summary

This is a prospective, randomized, comparative, clinical trial conducted by Wuhan Union Hospital that aims to evaluate the efficacy and safety of pioglitazone compared to placebo in patients with calcific aortic valve disease with mild aortic valve stenosis.

Conditions

  • Calcification of Aortic Valve
  • Aortic Valve Stenosis

Interventions

DRUG

Drug: Pioglitazone Oral Tablet

Dietary Supplement: Pioglitazone 30 mg by mouth daily

DIETARY_SUPPLEMENT

Placebo

Dietary: Supplement: Placebo

Sponsors & Collaborators

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2025-07-01
Completion
2028-07-01
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05875675 on ClinicalTrials.gov